From the publishers of JADPRO

MPN Resource Center


Predictors of response to hydroxyurea and switch to ruxolitinib in HU-resistant polycythaemia vera patients: A real-world PV-NET study

Last Updated: Wednesday, August 2, 2023

According to data from the real-world PV-NET trial of patients with polycythemia vera who were receiving hydroxyurea (HU) for ≥ 12 months, the absence of splenomegaly (p = 0.03), pruritus (p = 0.002), and a median HU dose of ≥ 1 g/day (p < 0.001) were associated with complete response. Among patients who achieved, partial or no response, 283 (71.3%) continued HU and 114 (28.7%) switched to ruxolitinib. The rates of thrombosis, hemorrhages, progression, and overall survival among patients receiving only HU were comparable among the complete, partial, and no response groups. This study confirmed the need to identify patients with suboptimal response to HU to improve overall therapeutic strategy, which was previously reported in MAJIC-PV and RESPONSE study.  

News & Literature Highlights

British Journal of Haematology

‘MPN Genomic Calculator’: real‐life use in a young population with essential thrombocythaemia


Significant association of cutaneous adverse events with hydroxyurea: results from a prospective non-interventional study in BCR-ABL1-negative myeloproliferative neoplasms (MPN) - on behalf of the German Study Group-MPN

Thrombosis Research

Patient outcomes in myeloproliferative neoplasm-related thrombosis: Insights from the National Inpatient Sample

British Journal of Haemtology

Real‐world non‐interventional long‐term post‐authorisation safety study of ruxolitinib in myelofibrosis

Cancer Medicine

Depressive symptoms and myeloproliferative neoplasms: Understanding the confounding factor in a complex condition

Expert Review of Hematology

Developing strategies to reduce the duration of therapy for patients with myeloproliferative neoplasms

European Society for Medical Oncology (ESMO) Congress 2021 Abstract

Final results of a phase II study of tipifarnib in chronic myelomonocytic leukemia (CMML) and other myelodysplastic/myeloproliferative neoplasms (MDS/MPN)

European Society for Medical Oncology (ESMO) Congress 2021 Abstract

Treatment outcomes and antibody immunity to SARS-CoV-2 in patients with hematological malignancies

Annals of Hematology

Evaluation of the need for cytoreduction and its potential carcinogenicity in children and young adults with myeloproliferative neoplasms

Clinical Lymphoma Myeloma and Leukemia

Mortality and causes of death of patients with polycythemia vera: analysis of the REVEAL prospective, observational study